|Chemical and physical data|
|Molar mass||151 kg/mol g·mol−1|
Dusigitumab is a human monoclonal antibody designed for the treatment of cancer. It binds to IGLF2. It was developed by MedImmune, which was acquired by AstraZeneca, using Xenomouse technology licensed from Abgenix.
Monoclonal antibodies for tumors
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|